A randomised phase III study of docetaxel versus active symptom control in patients with relapsed oesophago-gastric adenocarcinoma.

Trial Profile

A randomised phase III study of docetaxel versus active symptom control in patients with relapsed oesophago-gastric adenocarcinoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Jan 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms COUGAR02
  • Most Recent Events

    • 12 Mar 2014 Acruel to date is 102%.according to United Kingdom Clinical Research Network record.
    • 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 26 Jan 2013 Results presented at the 2013 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top